LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) (IMUC), a biotechnology company, today announced that the company has signed an agreement with Formatech, Inc. for the manufacture of IMUC’s cancer stem cell vaccine product candidate, ICT-121, for an upcoming clinical trial. The Phase I clinical trial of ICT-121 will target glioblastoma (brain cancer) and is expected to begin early next year, pending clearance by the FDA. ICT-121 is an “off-the-shelf” product, and this agreement calls for Formatech to prepare the vials of cancer vaccine for the clinical trial under a GMP (Good Manufacturing Practices) environment. ICT-121 is the company’s lead product candidate that targets cancer stem cells and may have applicability to multiple types of cancer.
